Amarin (NASDAQ:AMRN) has been given a $10.00 target price by Cantor Fitzgerald in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 177.78% from the stock’s previous close.
A number of other equities analysts have also commented on the company. ValuEngine lowered Amarin from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Zacks Investment Research lowered Amarin from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th. BidaskClub lowered Amarin from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Finally, HC Wainwright restated a “buy” rating on shares of Amarin in a research note on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $7.75.
Shares of Amarin (AMRN) opened at $3.60 on Monday. The firm has a market capitalization of $1,052.34, a P/E ratio of -14.40 and a beta of 0.57. The company has a debt-to-equity ratio of -1.12, a quick ratio of 1.13 and a current ratio of 1.41. Amarin has a fifty-two week low of $2.85 and a fifty-two week high of $4.60.
In other Amarin news, insider Steven B. Ketchum sold 135,205 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $4.41, for a total transaction of $596,254.05. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Steven B. Ketchum sold 64,683 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.40, for a total value of $284,605.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 426,720 shares of company stock worth $1,814,296. Corporate insiders own 3.72% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. State Street Corp increased its stake in shares of Amarin by 1.3% in the 2nd quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 2,640 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Amarin by 15.2% in the 2nd quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 5,000 shares during the last quarter. LPL Financial LLC increased its stake in shares of Amarin by 12.3% in the 4th quarter. LPL Financial LLC now owns 143,642 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 15,782 shares during the last quarter. Paloma Partners Management Co bought a new position in shares of Amarin in the 4th quarter valued at $141,000. Finally, Hoylecohen LLC bought a new position in shares of Amarin in the 4th quarter valued at $142,000. Hedge funds and other institutional investors own 38.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Amarin (AMRN) a $10.00 Price Target” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/03/12/cantor-fitzgerald-analysts-give-amarin-amrn-a-10-00-price-target.html.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.